scholarly journals Biochemical Markers of Bone Turnover in Rheumatoid Arthritis Patients Treated with Glucocorticoids

2019 ◽  
Vol 70 (2) ◽  
pp. 623-626
Author(s):  
Luana Andreea Macovei ◽  
Alexandra Burlui ◽  
Elena Rezus
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Biochemical Markers ◽  
Corticosteroid Treatment ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Bone Formation Marker ◽  
Markers Of Bone Turnover

Osteocalcin and deoxypyridinoline levels were measured in 55 RA patients during and after glucocorticoid therapy with prednisone, methylprednisolone and cortisone. A decrease of 27% of the bone resorption marker deoxypyridinoline (from 10.13 to 7.4) and an increase of 23% of the bone formation marker osteocalcin (from 16.3 to 20.1) were also clinically confirmed by the presence of osteoporosis in 74% of patients receiving corticosteroid treatment as compared with only 31% in the control group.

The changes in bone turnover markers of female systemic lupus erythematousus patients without glucocorticoid

Lupus ◽  
2021 ◽  
Vol 30 (6) ◽  
pp. 965-971
Author(s):  
Wang Tianle ◽  
Zhang Yingying ◽  
Hong Baojian ◽  
Gu Juanfang ◽  
Wang Hongzhi ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Bone Metabolism ◽  
Bone Turnover Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Amino Terminal ◽  
Normal People ◽  
Turnover Markers

Objectives SLE is a chronic autoimmune disease, which can affect the level of bone metabolism and increase the risk of osteoporosis and fracture. The purpose of this research is to study the effect of SLE on bone turnover markers without the influence of glucocorticoids. Methods A total of 865 female subjects were recruited from Zhejiang Provincial People’s Hospital and the First Hospital of Jiaxing, including 391 SLE patients without the influence of glucocorticoids and 474 non-SLE people. We detected Bone turnover markers including amino-terminal propeptide of type 1 procollagen (P1NP), C-terminal turnover of β - I collagen (β-CTX), N-terminal midfragment of osteocalcin (NMID) and 25(OH)D, and analyzed the difference in Bone turnover markers between the SLE group and the control group, as well as the influence of age and season on bone metabolism in female SLE patients. Results In the SLE group, the average age was 43.93±13.95 years old. In the control group, the average age was 44.84±11.42 years old. There was no difference between the two groups (t = 1.03, P = 0.30). P1NP, NMID and 25(OH)D in the SLE group were significantly lower than those in the control group (Z = 8.44, p < 0.001; Z = 14.41, p < 0.001; Z = 2.19, p = 0.029), and β-CTX in the SLE group was significantly higher than that in the control group (Z = 2.61, p = 0.009). In addition, the levers of β-CTX, NMID, P1NP and 25(OH)D in older SLE female patients were statistically significantly higher than those in younger (ρ = 0.104, p = 0.041; ρ = 0.223, p < 0.001; ρ = 0.105, p = 0.038; ρ = 0.289, p < 0.001). Moreover, β-CTX reached a high value in summer and PINP reached a low value in winter. Conclusion The bone formation markers of female SLE patients without glucocorticoid were lower than those of normal people and the bone resorption marker was higher than that of normal people. The 25 (OH) D of female SLE patients without glucocorticoid was lower than that of normal people. The risk of osteoporosis and fracture may be higher in elderly women with SLE. The bone resorption level of female SLE patients is high in summer and the bone formation level is low in winter.

Physical activity increases bone formation and decreases bone resorption as assessed by biochemical markers of bone turnover

1996 ◽  
Vol 6 (S1) ◽  
pp. 250-250
Author(s):  
HW Woitge ◽  
M Müller ◽  
P Bärtsch ◽  
B Friedmann ◽  
MJ Seibel ◽  
...  
Keyword(s):  
Physical Activity ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Biochemical Markers ◽  
Markers Of Bone Turnover

scholarly journals Bone markers and osteoporosis

2004 ◽  
Vol 23 (3) ◽  
pp. 221-228 ◽  
Author(s):  
Kaya Emerk
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Biochemical Markers ◽  
Alcohol Intake ◽  
Bone Markers ◽  
Bone Alkaline Phosphatase ◽  
Low Concentrations ◽  
Trabecular Microstructure ◽  
Markers Of Bone Turnover

Diagnosis of a given disease is often the first step to a successful therapy. The use of biochemical markers of bone turnover in osteoporosis is becoming more important due to their capacity to give early information. Many of the new markers are proteins, peptides, or other large biomolecules, usually present at very low concentrations. Bone is a living, growing tissue that turns over at a rate of about 10% a year. It is lergely made up of collagen, that gives the bone its tensile strength and framework, and calcium phosphate, mineralized complex that hardens the framework. After age 24, bone resorption slowly begins to happen faster than bone formation. Bone loss is most rapid in women in the first few year after menopause but continues into the postmenopausal years. Loss although much slowly, also happens in men. In addition to bone porosity, the bone strength is determined by the trabecular microstructure in wich osteoclastic, and osteoblastic activities play an important role. Osteoporosis develops when bone resorption occurs too rapidly and bone formation fails to keep up. Risk factors for osteoporosis involves age, gender, ethnicity, use of certain drugs, exercise, smoking Vit D deficiency, Ca intake, sex hormones, alcohol intake etc. Mineralization markers are serum osteocalcin, bone alkaline phosphatase, serum prokollagen I extention peptides. Markers for the resorption of bone on the other hand are urine N-telopeptide crosslinks, urine deoxy-piridinoline, urine hydroxyproline, tartarate dependent acid phosphatase and Catepsin K. Biochemical markers of bone turnover should be used with BMD for diagnosis.

scholarly journals PROGNOSTIC VALUE OF THE BONE TURNOVER MARKERS IN MULTIPLE MYELOMA

2017 ◽  
Vol 39 (1) ◽  
pp. 53-56 ◽  
Author(s):  
D Auzina ◽  
S Lejniece
Keyword(s):  
Multiple Myeloma ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Bone Disease ◽  
Diagnostic Marker ◽  
Control Group ◽  
Bone Lesions ◽  
Bone Resorption Marker ◽  
Baseline Values ◽  
Turnover Markers

Background: Multiple myeloma (MM) is characterized by osteolytic bone disease resulting from increased osteoclast activity and reduced osteoblast function. Aim: The aim of our research was to determine connection between bone turnover markers and presence of bone lesions, their degree of severity, to monitor MM bone disease and to assess effectiveness of anti-myeloma treatment. Materials and Methods: Serum samples and clinical data from 123 patients with newly diagnosed MM were collected at Riga East Clinical University Hospital (Riga, Latvia) from June 2014 to June 2016. Bone lesions detected by radiography, CT scans, MRI, and PET/CT were divided into degrees from 0 to 3 (0 — no bone involvement, 1 — ≤ 3 bone lesions, 2 — ≥ 3 bone lesions, 3 — fracture). Staging was performed applying Durie/Salmon (DS) and International Staging System classifications. Progressive disease was defined as development of one or more new bone lesions. The levels of bone metabolic markers β-isomerized C-terminal telopeptide of collagen type I (β-CTX) and bone-specific alkaline phosphatase (bALP) were monitored regularly in the year. Results: Bone lesions were found in 86 (69%) patients. From these 6 (4%) patients had 1st degree, 11 (9%) had 2nd degree and 69 (56%) had 3rd degree bone lesions. Level of the bone resorption marker β-CTX in the control group was 0.41 ng/ml, which is lower than in MM patients (p < 0.001). Spearman correlation coefficient analysis found a positive and statistically significant correlation (rs = 0.51, p < 0.001) between bone lesions degree and β-CTX levels. Mean β-CTX for patients without bone lesions was 0.72 ng/ml (SD = 0.64), but for patients with 3rd degree bone lesions it was 1.34 ng/ml (SD = 0.65) difference being 38% (p < 0.001). In patients who responded to therapy after 6 months of treatment reduction of β-CTX was found compared to baseline values (M = –0.65). In contrast, in patients who did not respond to therapy, there was a statistically significant (p < 0.001) increase in β-CTX values after six months of treatment compared to baseline values (M = 0.42). Exact cutoff value of β-CTX is 0.79. When analyzing mean bALP, no significant difference between MM patients and control group was found. ANOVA statistical analysis showed no statistically significant differences in bALP levels at different degrees of bone lesions (p = 0.95) in MM patients. Analysis of bALP suitability as MM diagnostic marker using receiver operating characteristics curve showed that bALP is not applicable for clinical diagnosis of MM (AUC 0.5, p > 0.05). However, β-CTX was found to be an excellent diagnostic marker for MM (AUC 0.91; 95% confidence interval, 0.88–0.94; p < 0.001). Conclusions: Patients with MM and bone lesions have increased value of bone resorption marker β-CTX. There is a correlation between bone resorption marker and degree of bone lesions. Changes in β-CTX levels may be used to monitor the effectiveness of myeloma treatment.

Weight-bearing exercise and markers of bone turnover in female athletes

2001 ◽  
Vol 90 (2) ◽  
pp. 565-570 ◽  
Author(s):  
Dana L. Creighton ◽  
Amy L. Morgan ◽  
Debra Boardley ◽  
P. Gunnar Brolinson
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Female Athletes ◽  
Weight Bearing ◽  
Calorie Intake ◽  
Mineral Density ◽  
High Group ◽  
Markers Of Bone Turnover ◽  
Total Body

Weight-bearing activity provides an osteogenic stimulus, while effects of swimming on bone are unclear. We evaluated bone mineral density (BMD) and markers of bone turnover in female athletes ( n = 41, age 20.7 yr) comparing three impact groups, high impact (High, basketball and volleyball, n= 14), medium impact (Med, soccer and track, n = 13), and nonimpact (Non, swimming, n = 7), with sedentary age-matched controls (Con, n = 7). BMD was assessed by dual-energy X-ray absorptiometry at the lumbar spine, femoral neck (FN), Ward's triangle, and trochanter (TR); bone resorption estimated from urinary cross-linked N-telopeptides (NTx); and bone formation determined from serum osteocalcin. Adjusted BMD (g/cm; covariates: body mass index, weight, and calcium and calorie intake) was greater at the FN and TR in the High group (1.27 ± 0.03 and 1.05 ± 0.03) than in the Non (1.05 ± 0.04 and 0.86 ± 0.04) and Con (1.03 ± 0.05 and 0.85 ± 0.05) groups and greater at the TR in the Med group (1.01 ± 0.03) than in the Non (0.86 ± 0.04) and Con (0.85 ± 0.05) groups. Total body BMD was higher in the High group (4.9 ± 0.12) than in the Med (4.5 ± 0.12), Non (4.2 ± 0.14), and Con (4.1 ± 0.17) groups and greater in the Med group than in the Non and Con groups. Bone formation was lower in the Non group (19.8 ± 2.6) than in the High (30.6 ± 3.0) and Med (32.9 ± 1.9, P ≤ 0.05) groups. No differences in a marker of bone resorption (NTx) were noted. This indicates that women who participate in impact sports such as volleyball and basketball had higher BMDs and bone formation values than female swimmers.

scholarly journals Low Dose Estrogen and Calcium Have an Additive Effect on Bone Resorption in Older Women1

1999 ◽  
Vol 84 (1) ◽  
pp. 179-183
Author(s):  
K. M. Prestwood ◽  
D. L. Thompson ◽  
A. M. Kenny ◽  
M. J. Seibel ◽  
C. C. Pilbeam ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Older Women ◽  
Low Dose ◽  
Type I Collagen ◽  
Control Group ◽  
Type I ◽  
Markers Of Bone Formation ◽  
Markers Of Bone Resorption

Previous studies have shown that treatment with estrogen or calcium decreases bone turnover in older women. The mechanisms by which estrogen and calcium exert their effects are probably different. We therefore examined the possibility of an additive or synergistic effect of combined treatment with calcium and low dose estrogen on bone turnover in older women, using biochemical markers. Thirty-one healthy women over 70 yr of age were randomized to 12 weeks of treatment with either micronized 17β-estradiol [0.5 mg/day Estrace (E2)] or 1500 mg/day elemental calcium, given as carbonate plus vitamin D (800 IU/day; Ca+D). At the end of the initial 12-week treatment period, both groups received both Ca+D and E2 for an additional 12 weeks. Eleven older women were followed for 36 weeks without any treatment and served as a control group. Serum and urine were collected at baseline, at 12 and 24 weeks on treatment, and at 12 weeks after treatment was terminated for measurement of biochemical markers of bone turnover. Markers of bone formation were bone alkaline phosphatase, osteocalcin, and type I procollagen peptide; markers of bone resorption were urinary cross-linked C-telopeptides and N-telopeptides of type I collagen, serum cross-linked N-telopeptides of type I collagen, urinary free deoxypyridinoline cross-links, and serum bone sialoprotein. Repeated measures ANOVA was used to determine changes in bone turnover measures over time by group. All markers of bone resorption decreased with initial treatment and decreased further with combination therapy (P &lt; 0.001). Markers of bone formation decreased with Ca+D treatment, but not with E2 alone; there was no additional effect of combination therapy on formation markers compared to Ca+D alone. Neither markers of formation nor resorption changed in the control group. These results suggest that there is an additive effect of low dose estrogen and calcium on bone resorption, but not on bone formation, in older women. Thus, the combination of low dose estrogen plus calcium is likely to be more effective in older women than either treatment alone.

scholarly journals Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans

2020 ◽  
Vol 4 (9) ◽  
Author(s):  
Louise L Lehrskov ◽  
Sasha Kjeldsen ◽  
Mark P Lyngbæk ◽  
Regitse Højgaard Chirstensen ◽  
Anne-Sophie Wedell-Neergaard ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Crossover Study ◽  
Bone Remodeling ◽  
Interleukin 6 ◽  
Plasma Concentrations ◽  
Bone Resorption Marker ◽  
Healthy Individuals ◽  
Bone Formation Marker ◽  
Double Blinded

Abstract Context Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited. Objective To investigate if IL-6 regulates bone remodeling in humans. Design Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies. Participants Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3. Interventions Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6. Main outcomes measures Effect of IL-6 on CTX levels. Results CTX was significantly (P &lt; 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3). Conclusions IL-6 may not regulate bone remodeling in humans.

Sign in / Sign up

Export Citation Format

Share Document